Osaka, Japan
Osaka, Japan

Takeda Pharmaceutical Company Ltd is the largest pharmaceutical company in Japan and Asia and a top 15 pharmaceutical company. The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Millennium: The Takeda Oncology Company. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo.In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. Wikipedia.


Time filter

Source Type

Patent
Takeda Pharmaceutical | Date: 2017-02-22

The present invention provides a fused heterocyclic compound that has CDK 8 and/or CDK 19 inhibitory activity. The present invention provides a compound represented by formula (I)


Patent
Takeda Pharmaceutical | Date: 2017-02-01

Provided is a compound having a superior PKC inhibitory action, and useful as a prophylactic or therapeutic agent for immune diseases, inflammatory diseases and the like, or a salt thereof. A compound represented by the formula (I):


Patent
Takeda Pharmaceutical | Date: 2017-02-15

Provided is a production method of a synthetic intermediate for a heterocyclic compound having a renin inhibitory activity and useful as a prophylactic or therapeutic drug for diabetic nephropathy, hypertension and the like. A production method of a compound represented by the formula (III-1a), the formula (III-1b), the formula (III-1c) and/or the formula (III-1d);


Patent
Takeda Pharmaceutical | Date: 2017-01-18

The present provides a pyridazine compound having an inhibiting effect on Stearoyl-CoA desaturase (SCD) (in particular, SCD1). The present provides a compound represented by formula


Patent
Takeda Pharmaceutical | Date: 2017-04-05

The present invention provides a novel technique for preserving a liquid pharmaceutical preparation safely and stably. The nano-bubble water of the present invention, which is produced in the presence of a surfactant, a hydrophilic resin and/or an electrolyte and contains not less than 2.010^(8) bubbles/mL of nano-bubbles, shows a superior antibacterial action, and can be preferably used as a base of a liquid pharmaceutical preparation showing safe and stable preservation property.


Patent
Takeda Pharmaceutical | Date: 2017-05-03

Provided is a compound having a superior acid secretion suppressive action, which shows an antiulcer activity and the like. A compound represented by the formula (I) or a salt thereof:R^(1) and R^(2) are each a cyclic group optionally having substituent(s); R^(3) and R^(4) are each H or alkyl, or R^(3) and R^(4) form, together with the adjacent N, an nitrogen-containing heterocycle; and Y is a spacer.


The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimers disease, schizophrenia, pain, sleep disorder, Parkinsons disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. (I) wherein each symbol is as described in the specification, or a salt thereof.


Provided are heterocyclic compounds having a RORt inhibitory action represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.


Patent
Takeda Pharmaceutical | Date: 2017-02-15

The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Downs syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimers disease, Parkinsons disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntingtons disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.


The present invention provides a compound useful as an agent for the prophylaxis or treatment of neurodegenerative disease and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Loading Takeda Pharmaceutical collaborators
Loading Takeda Pharmaceutical collaborators